拜瑞妥对静脉血栓的疗效

The drug (Rivaroxaban) is produced by the German company Bayer. It is a new, highly selective, new oral anticoagulant drug that can directly inhibit factor Xa. Its generic name is Varoxaban tablets. On the one hand, Xarelto can interrupt the intrinsic and extrinsic pathways of the coagulation cascade by inhibiting factor Xa. On the other hand, it can also inhibit thrombin and the generation and formation of thrombus. Thrombin (activated factor II) cannot be inhibited by rivaroxaban, and there is no clinical evidence that Xarelto has an effect on platelets.

In a randomized, double-blind phase III clinical study, 3396 patients with VTE were randomized to receive once-daily rivaroxaban (10 or 20 mg) or 100 mg aspirin. All patients completed 6 to 12 months of anticoagulant therapy before continuing. The primary endpoints of the trial were the incidence of symptomatic, recurrent, fatal or nonfatal venous thrombosis and the incidence of major bleeding.

The results showed that the incidence rate of thrombosis in the 20 mg rivaroxaban group was 1.5%, the 10 mg rivaroxaban group was 1.2%, and the aspirin group was 4.4% (95% CI 0.2-0.59 in the rivaroxaban group, 95% CI 0.14-0.47 in the aspirin group); the incidence rate of major bleeding was 0.5% vs 0.4% vs 0.3%, and the drug-related bleeding rate was 2.7%. vs 2.0% vs1.8% (20mg rivaroxaban vs 10mg rivaroxaban vs aspirin); the incidence of adverse events in each group was similar.

The results show that for patients with venous thrombosis who require continuous anticoagulation, 10 mg (preventive dose) and 20 mg (therapeutic dose) show better anti-thrombotic effects without increasing the risk of bleeding.